This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00044/identifier/wikipedia/
n16http://linked.opendata.cz/resource/AHFS/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00044/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n15http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00044/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00044/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00044/identifier/genbank/
n11http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00044/identifier/uniprotkb/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00044
rdf:type
n5:Drug
n5:description
Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH ("LH surge") triggers ovulation and the development of the corpus luteum. In males, it stimulates Leydig cell production of testosterone. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development.
n5:dosage
n20:271B416A-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3972 # Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1122882 # Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11476792 # Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20161981 # Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18627209 #Lutropin Alfa. In DynaMed [database online]. EBSCO Information Services. http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015. Updated January 18, 2013. Accessed October 1, 2014. #Lexicomp. Lutropin alfa. N.p., 2014. Web. 11 Nov. 2014. #EMD Serono, A Division of EMD Inc., Canada. Lutropin Alfa. Mississauga, Ontario: N.p., 2012.
n5:group
approved
n5:halfLife
Biphasic; terminal half-life is approximately 18 hours.
n5:indication
For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)
n5:manufacturer
n13:271B4168-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00044 n17:DB00044
dcterms:title
Lutropin alfa
adms:identifier
n4:PA164750539 n9:Lutropin_alfa n18:DB00044 n22:P01229 n23:X00264 n24:44087-1375-1
n5:mechanismOfAction
Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.
n5:packager
n13:271B4166-363D-11E5-9242-09173F13E4C5 n13:271B4167-363D-11E5-9242-09173F13E4C5
n5:patent
n12:5767251
n5:routeOfElimination
Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.
n5:synonym
LSH-B LH-B Lutropin alpha ICSH Lutropin beta chain precursor Luteinizing hormone LH Lutrophin Luteinizing hormone beta subunit Insterstiial cell-stimulating hormone LSH- beta
n5:toxicity
Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus.
n5:volumeOfDistribution
The steady state volume of distribution is around 10-14 L.
n10:hasAHFSCode
n16:68-18-00
foaf:page
n7:lutropin-alfa.html
n5:Molecular-Formula
n8:271B416F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n8:271B416E-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:G03GA07
n5:absorption
Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
152923-57-4
n5:category
n5:clearance
* 2 – 3 L/h [healthy female following subcutaneous administration]
n5:containedIn
n19:271B4169-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n8:271B416C-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n8:271B416D-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n8:271B416B-363D-11E5-9242-09173F13E4C5